Leukemia News and Research

RSS
Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia don't become apparent until a large number of normal blood cells are crowded out by leukemia cells.
Combination therapy safe and active in follicular lymphoma

Combination therapy safe and active in follicular lymphoma

New reports demonstrate the effectiveness of modified T cells in treating blood-borne cancers

New reports demonstrate the effectiveness of modified T cells in treating blood-borne cancers

Late-breaking abstracts on treatment of blood cancers and bleeding disorders presented at ASH meeting

Late-breaking abstracts on treatment of blood cancers and bleeding disorders presented at ASH meeting

New study may pave way for more effective treatment for deadly childhood cancer

New study may pave way for more effective treatment for deadly childhood cancer

New drug combination therapy effective for patients with HER2-positive breast cancer

New drug combination therapy effective for patients with HER2-positive breast cancer

Celgene subsidiary presents REVLIMID study results on lymphoma at ASH annual meeting

Celgene subsidiary presents REVLIMID study results on lymphoma at ASH annual meeting

Researchers personalizing cancer treatments for young patients

Researchers personalizing cancer treatments for young patients

Study shows children with ALL can safely receive intravenous infusions of chemotherapy

Study shows children with ALL can safely receive intravenous infusions of chemotherapy

Pharmacyclics presents ibrutinib trial data for B-cell malignancies at ASH meeting

Pharmacyclics presents ibrutinib trial data for B-cell malignancies at ASH meeting

Immunologists receive $4.8M grant to target multiple diseases by manipulating enzyme

Immunologists receive $4.8M grant to target multiple diseases by manipulating enzyme

FoundationOne Heme identifies clinically actionable genomic alterations in multiple myeloma cases

FoundationOne Heme identifies clinically actionable genomic alterations in multiple myeloma cases

ImmunoGen presents Phase I trial results of SAR650984 at ASH annual meeting

ImmunoGen presents Phase I trial results of SAR650984 at ASH annual meeting

Growing cord blood stem cells in lab before transplant boosts survival, study finds

Growing cord blood stem cells in lab before transplant boosts survival, study finds

NOXXON Pharma reports interim data from two phase IIa studies of anti-CXCL12/SDF-1 Spiegelmer NOX-A12

NOXXON Pharma reports interim data from two phase IIa studies of anti-CXCL12/SDF-1 Spiegelmer NOX-A12

Studies confirm superiority of Tasigna to Glivec at achieving molecular response in Ph+ CML patients

Studies confirm superiority of Tasigna to Glivec at achieving molecular response in Ph+ CML patients

CAR therapy shows potential for advancing treatment of patients with ALL and CLL

CAR therapy shows potential for advancing treatment of patients with ALL and CLL

Children and adults with high-risk ALL benefit from novel, personalized cell therapy

Children and adults with high-risk ALL benefit from novel, personalized cell therapy

New form of gene therapy shows promising outcomes for "bubble boy" disease

New form of gene therapy shows promising outcomes for "bubble boy" disease

Genetically engineered cell therapies demonstrate early efficacy, safety in patients with blood disorders

Genetically engineered cell therapies demonstrate early efficacy, safety in patients with blood disorders

Gemtuzumab with standard chemotherapy can reduce risk of relapse in pediatric patients with AML

Gemtuzumab with standard chemotherapy can reduce risk of relapse in pediatric patients with AML

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.